Main Page

From DrugPedia: A Wikipedia for Drug discovery

(Difference between revisions)
Jump to: navigation, search
m (Reverted edits by AnupamMittal (Talk) to last version by Raghavagps)
Line 1: Line 1:
   
   
-
                                          '''Where are we standing?????????????????????'''
+
Consult the [http://meta.wikimedia.org/wiki/Help:Contents User's Guide] and [[manual:FAQ|FAQ]] for information on using the wiki software.
-
After 126 years, the etiological agent of deadly tuberculosis (http://en.wikipedia.org/wiki/Tuberculosis) has been discovered by Robert Koch, we have only one vaccine and few countable antibiotics against tuberculosis. Is this justifiable?
+
-
Recent estimates of Tuberculosis disease is approximately 1.86 billion people with 16.2 million cases of active diseases. (Dye etal.,1999). It’s a fact and I also support that not a single treatment but a combinatorial approach is required against this culprit. We are living in the age of biotechnology and Nanotechnology so we should look for molecular medicine which may be some involve synthetic  molecules mimicking that in system approaches. Through this article I have tried to make people think about the computers, biomolecules and some naturally occurring compounds as a combinatorial approach to fight the evil like tuberculosis.  
+
== CRDD at OSDD ==
 +
Government of India & [http://www.csir.res.in/ Council of Scientific & Industrial Research] (CSIR) plan to initiate an [http://www.osdd.org Open Source Drug Discovery] (OSDD) programme under the able guidance of Visionary Scientist & Current Director General. OSDD Forum is an initiative with a vision to provide affordable healthcare to the developing world by providing a global platform where the best brains can collaborate & collectively endeavor to solve the complex problems associated with discovering novel therapies for diseases like Malaria, Tuberculosis, Leshmaniasis, etc. These diseases persist mainly in the third world countries. Tuberculosis (TB), for example, is a ravaging dreaded disease killing one person in every 1.5 minutes in India. Nearly 2 billion people are infected, i.e., 1 in 3 of global population. 8.9 million new cases have been reported in 2004 of which 80% are from the 22 high-burden countries alone.  
-
In my this article I am suggesting one of my idea although its very older approach which has been discovered in 20th century that is Antisense DNA technology (http://en.wikipedia.org/wiki/Antisense_therapy). I have targeted the dna N gene (Gene ID 887092) (http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=57116681 from 2052 to 3260) of Mycobacterium tuberculosis H37Rv strain which is a DNA Polymerase III and is a complex, multi-chain enzyme responsible for most of the replicative process in bacteria. This DNA polymerase also exhibits 3' to 5' exonuclease activity.  
+
Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs for TB. The OSDD concept aims to synergise the power of genomics, computational technologies and participation of young and brilliant talent from Universities and industry towards a concerted effort to address this important scourge. The success stories of Open source approach in IT and in the Human genome Sequencing Project further underline the usefulness of such an approach in health care. India is one of the leading countries in Information technology. One of the key features of the OSDD programme is to use our expertise in IT towards drug discovery.
-
A brief description of the method is as follows:
+
[http://crdd.osdd.net Computational Resources for Drug Discovery] (CRDD) programme has been designed under OSDD to develop the portals that may accelerate the drug discovery process and bring down the cost of the drug. It will serve as the platform for interaction among researchers and for storage, retrieval and analysis of biological data.  As an incentive to the participants innovative solutions will be rewarded. “Open Source Drug Discovery” envisions the participation of scientists and students in growing numbers as the momentum of the Open Source movement grows. OSDD is committed to provide a World Class Portal in Open Source Mode to build and coalesce user community including tapping intelligent minds for affordable drug development.
-
 
+
-
•The sequence of the dna N gene has been analyzed for GC rich region which is from 2152 to 2172 of coding region (Total length of dna N gene in the genome of Mycobacterium 2052 to 3260).
+
-
 
+
-
•The sequence was aligned with both the human genome (host of Mycobacterium tuberculosis) and Mycobacterium genome itself using the BLAST tool.
+
-
 
+
-
•It was found that there was no significant homology between the genome of human and the oligonucleotide we are going to use for Antisense against dna N gene. This shows that the oligo would act specifically against Mycobacterium.
+
-
 
+
-
•It was also observed that the oligo has homology with other gene of Mycobacterium tuberculosis H37Rv strain.
+
-
 
+
-
•Then an expression vector (eg:  pCS 105 vector modified by Duve Turner’s) has been designed that will produce the antisense against the transcribed portion of dna N gene.
+
-
 
+
-
•This vector has been transfected into the cell.
+
-
 
+
-
•The vector would transcribe the antisense and this antisense result in DNA/RNA hybrid and RNase H degrade that hybrid resulting in no translation and killing of our target.
+
-
   
+
-
           
+
-
References:
+
-
Dye,C., Scheele,S., Dolin,P., Pathania,V., and Raviglione,R.C. (1999). Global burden of tuberculosis—estimated incidence, prevalence, and mortality by country. J. Am. Med. Assn. 282,677–686
+

Revision as of 00:25, 6 September 2008

Consult the User's Guide and FAQ for information on using the wiki software.

CRDD at OSDD

Government of India & Council of Scientific & Industrial Research (CSIR) plan to initiate an Open Source Drug Discovery (OSDD) programme under the able guidance of Visionary Scientist & Current Director General. OSDD Forum is an initiative with a vision to provide affordable healthcare to the developing world by providing a global platform where the best brains can collaborate & collectively endeavor to solve the complex problems associated with discovering novel therapies for diseases like Malaria, Tuberculosis, Leshmaniasis, etc. These diseases persist mainly in the third world countries. Tuberculosis (TB), for example, is a ravaging dreaded disease killing one person in every 1.5 minutes in India. Nearly 2 billion people are infected, i.e., 1 in 3 of global population. 8.9 million new cases have been reported in 2004 of which 80% are from the 22 high-burden countries alone.

Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs for TB. The OSDD concept aims to synergise the power of genomics, computational technologies and participation of young and brilliant talent from Universities and industry towards a concerted effort to address this important scourge. The success stories of Open source approach in IT and in the Human genome Sequencing Project further underline the usefulness of such an approach in health care. India is one of the leading countries in Information technology. One of the key features of the OSDD programme is to use our expertise in IT towards drug discovery.

Computational Resources for Drug Discovery (CRDD) programme has been designed under OSDD to develop the portals that may accelerate the drug discovery process and bring down the cost of the drug. It will serve as the platform for interaction among researchers and for storage, retrieval and analysis of biological data. As an incentive to the participants innovative solutions will be rewarded. “Open Source Drug Discovery” envisions the participation of scientists and students in growing numbers as the momentum of the Open Source movement grows. OSDD is committed to provide a World Class Portal in Open Source Mode to build and coalesce user community including tapping intelligent minds for affordable drug development.

Retrieved from "http://277988.efsst.group/drugpedia/index.php/Main_Page"